MEM
Pharmaceuticals, Biotechnology & Life Sciences
Memphasys
- Short interest
- 0.00%
- 0.00 pp 30d
- as of 14 May 2021
- Reported shorts
- 9.1K
- Shares on issue
- 759.774M
Memphasys (MEM) company profile
Profile, insiders and operations
Company
AI-generated research profile of Memphasys
biotechnology
reproductive health
Felix System
ASX
innovation
Memphasys Limited specializes in advanced biological separations, focusing on reproductive biotechnology. The company leverages its proprietary technologies, Felix™ and RoXsta™, to enhance assisted reproductive treatments for both humans and animals. Memphasys is strategically positioned in the market with its innovative solutions aimed at bridging gaps in assisted reproductive technology.
MEM intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Sign in to unlock the dossierFree account · no card required